Keyword: Teva Pharmaceutical
Sanofi's Dupixent picked up its important asthma approval on Friday, setting the drug up for a multibillion-dollar peak sales boost.
Allergan and Eli Lilly won coverage from PBM giant Express Scripts for their new migraine launches, but Teva's Ajovy was left out in the cold.
Teva lost a patent appeal for multiple sclerosis blockbuster Copaxone, a drug that has seen a considerable sales decline due to generics.
Teva’s Copaxone has hung on to market share even in the face of oral competitors and generics. But Novartis aims to change that.
An independent panel of FDA advisers endorsed Celltrion’s Rituxan biosimilar, sending the program to the FDA for a final say.
Israel-based Teva, whose pledge to unload manufacturing plants in its home country sparked strikes, is reportedly close to selling a site there.
Ahead of an FDA panel meeting for Celltrion's Rituxan biosimilar, agency reviewers noted "clinically meaningful differences" between the products.
Last week, investors concerned about generics trends and migraine competition cratered Teva’s shares. But did they need to worry? Analysts disagree.
Sales of Lilly's Cialis are set to fall from $2.3 billion a year to $55 million, pressuring the company to forge new lucrative markets.
Eli Lilly may not be first to market in the CGRP field, but an exec says a few factors in its Emgality launch will help the company beat its rivals.